1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Acrux Limited

Acrux Limited

0.01
USD
+0.01
(+5,864.00%)
0.00EPS
8.57MMarket Cap
Mar 02Next Earn
Acrux Limited
OTC:ARUXF
(OTC Markets)

Recent

price

0.01

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
AUD
0.54
0.05
0.09
0.32
0.15
0.17
0.14
0.02
- -
0.01
0.01
0.01
0.03
0.02
- -
0.01
Revenue per Share
0.35
0.04
0.04
0.17
0.07
0.08
- -
-0.09
-0.05
-0.06
-0.06
-0.03
- -
-0.02
-0.02
- -
Basic EPS, GAAP
0.39
-0.02
0.04
0.22
0.06
0.1
0.03
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
0.6
- -
0.08
0.2
0.08
0.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.27
0.32
0.28
0.25
0.24
0.26
0.26
0.18
0.13
0.08
0.07
0.03
0.03
0.01
- -
- -
Book Value per Share
0.27
0.32
0.28
0.25
0.12
0.15
0.22
0.18
0.13
0.07
0.06
0.03
0.03
0.01
- -
- -
Tangible Book Value per Share
165
166
167
167
167
167
167
167
167
168
220
284
286
289
352
423
Basic Weighted Avg Shares
90
9
16
53
25
28
23
3
1
1
1
2
8
5
1
4
Sales/Revenue/Turnover
92.98
37.16
60.86
87
68.71
68.92
45.31
-408.67
-2,058.64
-963.85
-1,215.48
-754.28
-40.22
-168.43
-753.95
-57.82
Operating Margin (%)
- -
- -
1
1
1
1
2
1
- -
1
1
1
1
1
- -
- -
Depreciation Expense
57
7
7
28
11
13
- -
-14
-8
-9
-13
-10
-1
-6
-6
-1
Net Income, GAAP
30.74
- -
31.02
36.22
33.77
28.25
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
63.78
84.02
44.54
52.41
45.21
46.35
-1.04
-527.8
-1,319.33
-755.87
-944.58
-572.08
-9.06
-113.93
-499.58
-14.05
Profit Margin (%)
51
32
26
25
25
28
36
26
19
10
16
7
8
2
- -
1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
2
2
2
2
1
LT Debt
46
53
47
42
41
44
44
30
22
13
18
9
9
3
1
1
Total Equity
86.18
- -
12.79
62.33
25.18
30.85
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
89.13
- -
13.87
62.99
26.92
30.72
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
89.13
14.96
13.87
62.99
26.92
30.72
-0.55
-38.38
-32.08
-54.45
-80.64
-71.36
-8.59
-96.89
-276.58
-48.51
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-19.9%
-28.56%
43.4%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
609.76%
91.49%
-89.84%
Sales/Revenue/Turnover
48.74%
112.77%
261.18%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
5
2025
- -
- -
1
2026
- -
- -
4

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.02
2025
- -
- -
-0.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Acrux Limited Acrux Limited is an Australia-based specialty pharmaceutical company focused on developing, registering, and commercializing a portfolio of topically applied generic pharmaceutical products, with primary emphasis on the US market; its core offerings include transdermal and topical prescription pharmaceuticals such as testosterone topical solutions, nitroglycerin ointments, acne treatments, Lenzetto, Evamist, Axiron, Ellavie, and Recuvyra, leveraging proprietary technology for drug administration through the skin, on-site laboratories, and GMP manufacturing suite. Founded in 1998 and headquartered in West Melbourne, Victoria, the company operates in Australia, the United States, Europe, and other regions, deriving revenue from licensing and commercialization partnerships while targeting affordable generic alternatives in dermatology, hormone therapy, and cardiovascular segments. Recent developments include multiple capital raisings such as $1.34 million from SPP in December 2024 and placements in early 2025 to directors including CEO Ross Dobinson and Chairman Donald Brumley; US FDA acceptance of generic applications like nitroglycerin ointment and positive remote regulatory assessments; terminations of commercialization agreements with partners including Dash Pharmaceuticals, Amring Pharmaceuticals, TruPharma, and Harris; and director share acquisitions via exercised rights and placements in 2025, reflecting ongoing funding for pipeline advancement amid a focus on topical generics.